What is HC Wainwright’s Forecast for OmniAb FY2025 Earnings?

OmniAb, Inc. (NASDAQ:OABI) – Investment analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of OmniAb in a research note issued on Wednesday, November 5th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.50) per share for the year, up from their previous estimate of ($0.59). The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s Q4 2025 earnings at ($0.06) EPS, FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($0.32) EPS, FY2028 earnings at ($0.18) EPS and FY2029 earnings at ($0.16) EPS.

OmniAb (NASDAQ:OABI) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. The business had revenue of $2.24 million for the quarter, compared to analyst estimates of $5.64 million. OmniAb had a negative net margin of 301.83% and a negative return on equity of 23.14%. OmniAb has set its FY 2025 guidance at EPS.

Several other equities analysts have also issued reports on OABI. Royal Bank Of Canada decreased their price target on shares of OmniAb from $4.00 to $3.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of OmniAb in a report on Tuesday, October 14th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $6.67.

OmniAb Stock Performance

Shares of NASDAQ:OABI opened at $1.38 on Friday. The company has a 50 day moving average price of $1.61 and a two-hundred day moving average price of $1.70. The company has a market capitalization of $198.66 million, a PE ratio of -2.38 and a beta of 0.15. OmniAb has a 52 week low of $1.22 and a 52 week high of $4.71.

Hedge Funds Weigh In On OmniAb

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. raised its stake in shares of OmniAb by 214.4% in the 2nd quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock valued at $25,000 after purchasing an additional 9,716 shares during the period. AQR Capital Management LLC bought a new position in shares of OmniAb during the first quarter worth about $25,000. Cerity Partners LLC bought a new position in shares of OmniAb during the first quarter worth about $26,000. PNC Financial Services Group Inc. raised its position in OmniAb by 279.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 16,276 shares of the company’s stock valued at $39,000 after buying an additional 11,986 shares during the last quarter. Finally, Corient Private Wealth LLC bought a new stake in OmniAb in the 2nd quarter valued at approximately $53,000. 72.08% of the stock is owned by institutional investors and hedge funds.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.